Nuvectis Pharma, Inc.
NVCT
Výsledovka
Rozvaha
Peněžní toky
Ukazatele
Klíčové metriky
V miliónech (USD)
| Revenue | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|---|
| Total Revenues | 0.00 | 0.00 | 0.00 | 0.00 | 149.00 | 0.00 | |
| Cost of Revenues | 0.00 | 0.00 | 0.00 | 22,897.00 | 19,234.00 | 12,894.00 | |
| Gross Profit | 0.00 | 0.00 | 0.00 | -22,897.00 | -19,085.00 | -12,894.00 | |
| Operating Income | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|---|
| R&D Expenses | 0.00 | 0.00 | 0.00 | 15,380.00 | 13,227.00 | 9,545.00 | |
| Selling General & Admin Expenses | 0.00 | 0.00 | 0.00 | 7,517.00 | 6,007.00 | 3,349.00 | |
| Depreciation & Amortization | 0.00 | 0.00 | 0.00 | -1,000.00 | 0.00 | 0.00 | |
| Total Operating Expenses | 27,574.00 | 27,574.00 | 19,847.00 | 22,897.00 | 19,234.00 | 12,894.00 | |
| Operating Income | 0.00 | 0.00 | -19,847.00 | -22,897.00 | -19,234.00 | -12,894.00 | |
| Net Income | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|---|
| Interest Income | 0.00 | 0.00 | 847.00 | 637.00 | 149.00 | 4.00 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 149.00 | 0.00 | |
| Other Expense | 0.00 | 0.00 | 847.00 | 637.00 | 149.00 | 4.00 | |
| IBT | -28,871.00 | -28,871.00 | -19,000.00 | -22,260.00 | -19,085.00 | -12,890.00 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | -298.00 | -4.00 | |
| Net Income | -28,871.00 | -28,871.00 | -19,000.00 | -22,260.00 | -18,787.00 | -12,886.00 | |
| Per Share Data | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|---|
| EPS | $0.00 | $0.00 | $0.00 | $-1.43 | $-1.48 | $-1.01 | |
| EPS Diluted | $0.00 | $0.00 | $0.00 | $-1.43 | $-1.48 | $-1.01 | |
| Shares Outstanding | 21,812.72 | 21,812.72 | 17,113.17 | 15,556.66 | 12,657.65 | 12,717.79 | |
| Diluted Shares Outstanding | 21,812.72 | 21,812.72 | 17,113.17 | 15,556.66 | 12,657.65 | 12,717.79 | |
| Current Assets | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|---|
| Cash And Equivalents | 18,116.00 | 18,533.00 | 19,126.00 | 19,993.00 | 5,742.00 | 0.00 | |
| Short Term Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Total Cash & ST Investments | 18,116.00 | 18,533.00 | 19,126.00 | 19,993.00 | 5,742.00 | 0.00 | |
| Accounts Receivable | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Inventory | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Current Assets | 182.00 | 74.00 | 59.00 | 412.00 | 91.00 | 0.00 | |
| Total Current Assets | 18,298.00 | 18,607.00 | 19,185.00 | 20,405.00 | 5,833.00 | 0.00 | |
| Long-Term Assets | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|---|
| Net Property, Plant & Equipment | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Goodwill | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Intangible Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Long-Term Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Long-Term Assets | 0.00 | 0.00 | 0.00 | 0.00 | 824.00 | 0.00 | |
| Total Long-Term Assets | 0.00 | 0.00 | 0.00 | 0.00 | 824.00 | 0.00 | |
| Total Assets | 18,298.00 | 18,607.00 | 19,185.00 | 20,405.00 | 6,657.00 | 0.00 | |
| Current Liabilities | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|---|
| Accounts Payable | 1,846.00 | 2,498.00 | 2,771.00 | 2,910.00 | 1,058.00 | 10.00 | |
| Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Current Liabilities | 3,924.00 | 6,396.00 | 4,213.00 | 3,276.00 | 1,361.00 | 0.00 | |
| Current Liabilities | 5,770.00 | 8,894.00 | 6,984.00 | 6,186.00 | 2,419.00 | 10.00 | |
| Long-Term Liabilities | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|---|
| Long-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Capital Leases | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Def. Tax Liability | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Total Liabilities | 5,770.00 | 8,894.00 | 6,984.00 | 6,186.00 | 17,665.00 | 10.00 | |
| Total Common Equity | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|---|
| Common Stock | 18,652,688.00 | 0.00 | 0.00 | 14,752,403.00 | 0.00 | 0.00 | |
| Retained Earnings | -62,844.00 | -73,245.00 | -54,245.00 | -31,985.00 | -12,900.00 | -10.00 | |
| Comprehensive Income | 0.00 | 0.00 | 0.00 | -14,752,403.00 | 0.00 | 0.00 | |
| Total Common Equity | 12,528.00 | 9,713.00 | 12,201.00 | 14,219.00 | -11,008.00 | -10.00 | |
| Cash Flow From Operating Activities | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|---|
| Net Income | -21,102.00 | -26,442.00 | -19,000.00 | -22,260.00 | -19,085.00 | -12,890.00 | |
| Depreciation & Amortization | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Stock-Based Compensation | 4,911.00 | 1,351.00 | 4,858.00 | 4,705.00 | 1,707.00 | 1,892.00 | |
| Change Working Capital | 1,719.00 | 0.00 | 1,895.00 | 1,740.00 | 3,819.00 | 1,494.00 | |
| Change In Accounts Receivable | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Change In Accounts Payable | -904.00 | 3,776.00 | -273.00 | -139.00 | 0.00 | 1,585.00 | |
| Change In Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Non-cash Items | 5,815.00 | 9,082.00 | 0.00 | -139.00 | 0.00 | 0.00 | |
| Cash from Operations | -14,472.00 | 0.00 | 0.00 | -15,954.00 | -13,559.00 | -9,504.00 | |
| Cash Flow From Investing Activities | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|---|
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Sales of Investment | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cash from Investing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cash Flow From Financing Activities | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|---|
| Debt Repaid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Debt Issued | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Issuance of Common Stock | 8,411.00 | 0.00 | 0.00 | 5,289.00 | 31,879.00 | 0.00 | |
| Repurchase of Common Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Financing Activities | -615.00 | 0.00 | 0.00 | 9,798.00 | -4,069.00 | 15,246.00 | |
| Cash from Financing | 7,988.00 | 0.00 | 0.00 | 15,087.00 | 27,810.00 | 15,246.00 | |
| Cash position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|---|
| Net Change in Cash | -6,484.00 | 13,101.00 | -593.00 | -867.00 | 14,251.00 | 5,742.00 | |
| Closing Cash Balance | 18,116.00 | 31,634.00 | 18,533.00 | 19,126.00 | 19,993.00 | 5,742.00 | |
| Free Cash Flow | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|---|
| Free Cash Flow | -14,472.00 | -16,009.00 | -12,247.00 | -15,954.00 | -13,559.00 | -9,504.00 | |
| Real Free Cash Flow | -19,383.00 | -17,360.00 | -17,105.00 | -20,659.00 | -15,266.00 | -11,396.00 | |
| Nacenění | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|---|
| P/E | -6.30 | -4.87 | -5.83 | -5.05 | -3.21 | -4,133.28 | |
| P/EG | -0.64 | 0.22 | 1.73 | -0.11 | 0.00 | 0.00 | |
| P/B | 9.46 | 9.53 | 10.63 | 6.68 | -3.75 | -4,133.28 | |
| P/S | 0.00 | 0.00 | 0.00 | 637.13 | 0.00 | 0.00 | |
| P/FCF | -11.85 | -7.56 | -8.13 | -7.00 | -4.35 | 1,722.20 | |
| P/OFC | -11.85 | -7.56 | -8.13 | -7.00 | -4.35 | 1,722.20 | |
| Price/EV | -5.24 | -3.90 | -4.83 | -3.90 | -2.76 | 0.00 | |
| Marže | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% | -12,808.7% | 0.0% | 0.0% | |
| EBIT Margin | 0.0% | 0.0% | 0.0% | -12,808.7% | 0.0% | 0.0% | |
| EBITDA Margin | 0.0% | 0.0% | 0.0% | -12,908.7% | 0.0% | 0.0% | |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% | -12,908.7% | 0.0% | 0.0% | |
| Net Profit Margin | 0.0% | 0.0% | 0.0% | -12,608.7% | 0.0% | 0.0% | |
| Finanční zdraví | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|---|
| Current Ratio | 2.66 | 2.09 | 2.75 | 3.30 | 2.41 | 0.00 | |
| Quick Ratio | 2.66 | 2.09 | 2.75 | 3.30 | 2.41 | 0.00 | |
| Solvency Ratio | -0.62 | -2.14 | -3.33 | -3.23 | -1.13 | 1.40 | |
| Cash Ratio | 2.64 | 2.08 | 2.74 | 3.23 | 2.37 | 0.00 | |
| Debt To Assets Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Debt To Equity Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Financial Leverage Ratio | 1.60 | 1.92 | 1.57 | 1.44 | -0.60 | 0.00 | |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | -127.09 | 0.00 | 0.00 | |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | -129.09 | 0.00 | 0.00 | |
| Data na akcii | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|---|
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | |
| Net Income Per Share | -1.13 | -1.11 | -1.43 | -1.48 | -1.01 | 0.00 | |
| Cash Per Share | 1.25 | 1.08 | 1.23 | 1.58 | 0.45 | 0.00 | |
| Shareholders Equity Per Share | 0.79 | 0.57 | 0.78 | 1.12 | -0.87 | 0.00 | |
| Free Cash Flow Per Share | -0.63 | -0.72 | -1.03 | -1.07 | -0.75 | 0.00 | |
| Dividend Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Efektivita | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|---|
| Effective Tax Rate | 0.0% | 0.0% | 0.0% | 1.6% | 0.0% | 0.2% | |
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Payables Turnover | 1.93 | 0.00 | 8.26 | 6.61 | 12.19 | 0.00 | |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.02 | 0.00 | 0.00 | |
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
